Quantcast
Last updated on April 20, 2014 at 21:20 EDT

First Patient Treated in Trillium’s Interstitial Cystitis/Bladder Pain Syndrome Clinical Trial

March 28, 2012

TORONTO, March 28, 2012 /PRNewswire/ – Trillium Therapeutics Inc., a
privately-held biopharmaceutical company developing proprietary and
innovative biologic therapies, today announced that it has dosed the
first patient in a phase I clinical trial evaluating TTI-1612, an
investigational agent in development for the treatment of interstitial
cystitis/bladder pain syndrome (IC/BPS). The study is designed to
evaluate the safety and pharmacokinetics of single ascending doses of
TTI-1612 in IC/BPS patients. It is being conducted at multiple sites
across Southern Ontario and is currently recruiting subjects.

“The start of patient dosing represents a major first step towards a new
and innovative treatment option for millions of people who suffer with
IC/BPS”, commented Trillium’s Director, Drug Development, Dr. Penka
Petrova. “We look forward to expanding this program into the United
States and beyond with the start of our next trial in 2013″.

IC/BPS, also known as painful bladder syndrome, is a chronic,
debilitating and poorly treated bladder disease affecting millions of
people. The disease is believed to develop as a result of dysfunction
in the protective epithelial layer lining the bladder. Working with a
premier advisory group of leading urologists, Trillium has assembled a
robust development program aimed at addressing the underlying cause of
IC/BPS. TTI-1612, recombinant growth factor that is administered
directly into the bladder, is being developed to correct the
dysfunction and restore the bladder epithelium to a normal, healthy
state.

“The start of clinical development is a key milestone for Trillium,
which will better position us to initiate partnership discussions with
leading drug developers, as well as to attract interest from
prospective investors. The company intends to secure additional
financing in 2012 prior to the start of randomized efficacy studies in
2013″, added Trillium’s CEO, Dr. Niclas Stiernholm.

More information regarding this trial is available on the U.S. National
Institutes of Health clinical trials database at www.clinicaltrials.gov (identifier NCT01559961).

About Interstitial Cystitis /Bladder Pain Syndrome (IC/BPS)

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic
bladder disease that primarily affects women. It is characterized by
increased urinary urgency and/or frequency, nocturia (waking from sleep
to urinate) and pelvic pain. These symptoms are often severe, and can
impact both the physical and emotional health of patients. For many
IC/BPS sufferers, the disease adversely affects all major aspects of
their lives, including social relationships, travel, leisure activities
and employment. Once considered a rare disease, IC/BPS is now
recognized as an increasingly common medical problem. Recently, a large
epidemiological study found that 3.3 to 7.9 million women in the US
alone suffer from IC symptoms. Current therapies often provide
inadequate relief, and many IC/BPS patients report dissatisfaction with
available treatment options. Since the current pipeline of new IC/BPS
drugs is largely focused on analgesics and is unlikely to significantly
alter the IC treatment landscape, novel and innovative approaches to
treatment are needed.

About Trillium:

Trillium Therapeutics Inc. is a private biopharmaceutical company
specializing in innovative therapies in two main areas: cytoprotection
and immune regulation. The company’s most advanced program, TTI-1612,
is a cytoprotective recombinant growth factor that is being developed
for the treatment of interstitial cystitis.  The company also has a
long-standing interest in the field of immune regulation, in particular
the negative pathways that malignant cells exploit to suppress
anti-tumour responses. Trillium currently has two preclinical programs,
CD200 mAb and SIRPaFc, that target two key immunoregulatory pathways
that tumour cells exploit to evade the host immune system. The CD200
mAb is fully human monoclonal antibody that blocks the activity of
CD200, an immunosuppressive molecule that is overexpressed by many
hematopoietic and solid tumours. SIRPaFc is fusion protein that blocks
the activity of CD47, a molecule that is upregulated on cancer stem
cells in AML and other tumours. Trillium has a broad network of
external academic and industry R&D collaborations, and is supported by
three premier Canadian venture capital investors: Covington Capital,
Growthworks and BDC Capital.

SOURCE Trillium Therapeutics Inc.


Source: PR Newswire